D75.2 Essential thrombocytosis

Name of the Condition

• Essential thrombocytosis

Summary

Essential thrombocytosis is a myeloproliferative neoplasm characterized by the overproduction of platelets in the bone marrow. This results in elevated platelet counts, which can increase the risk of thrombotic or hemorrhagic events. The condition is a clonal disorder, meaning it originates from a single abnormal cell, and typically occurs in adults, though it can affect younger individuals. Unlike secondary causes of thrombocytosis, essential thrombocytosis is not associated with an identifiable underlying condition or reactive process.

Causes

Essential thrombocytosis is caused by genetic mutations, most commonly in the JAK2, CALR, or MPL genes, which regulate blood cell production. These mutations lead to uncontrolled proliferation of megakaryocytes (platelet-producing cells) in the bone marrow. The exact trigger for these mutations is not fully understood, but they result in a clonal expansion of platelet-producing cells, driving the elevated platelet count.

Risk Factors

• Age (more common in adults, particularly those over 50).
• Genetic predisposition, including mutations in JAK2, CALR, or MPL genes.
• Prior history of myeloproliferative neoplasms or related blood disorders.

Symptoms

• Headaches, dizziness, or visual disturbances due to microvascular occlusions.
• Erythromelalgia (burning pain and redness in the hands or feet).
• Thrombotic events, such as deep vein thrombosis, stroke, or heart attack.
• Hemorrhagic symptoms, including easy bruising, nosebleeds, or gastrointestinal bleeding.
• Splenomegaly (enlarged spleen) in some cases.

Diagnosis

Diagnosis involves confirming a sustained elevated platelet count (typically >450,000/µL) without a secondary cause. Laboratory tests include a complete blood count (CBC) to assess platelet levels, iron studies to rule out iron deficiency, and genetic testing for JAK2, CALR, or MPL mutations. Bone marrow biopsy may be performed to evaluate megakaryocyte morphology and exclude other myeloproliferative disorders.

Treatment Options

Treatment aims to reduce platelet counts and prevent complications. Options include:

• Low-dose aspirin to reduce thrombotic risk (if no contraindications).
• Cytoreductive therapy (e.g., hydroxyurea, anagrelide) to lower platelet counts in high-risk patients.
• Interferon-alpha for patients who cannot tolerate other therapies or during pregnancy.
• Phlebotomy to manage symptoms of hyperviscosity, though less common than in polycythemia vera.

Prognosis and Follow-Up

Prognosis is generally favorable, but the risk of thrombotic or hemorrhagic events varies by patient. Regular monitoring of platelet counts, blood counts, and symptoms is essential. Follow-up may include periodic CBCs, assessment for splenomegaly, and evaluation for signs of progression to myelofibrosis or acute leukemia. Risk stratification guides treatment intensity and surveillance frequency.

Complications

• Thrombotic events (e.g., stroke, myocardial infarction, deep vein thrombosis).
• Hemorrhagic complications (e.g., gastrointestinal bleeding, intracranial hemorrhage).
• Progression to myelofibrosis or acute myeloid leukemia in a small subset of patients.
• Erythromelalgia or other microvascular symptoms.

Lifestyle & Prevention

• Avoid smoking and excessive alcohol, which may increase thrombotic risk.
• Stay hydrated to reduce blood viscosity.
• Use protective measures (e.g., padding) to prevent injury and bleeding.
• Follow up regularly with a hematologist for monitoring and management.

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden severe headache, chest pain, or shortness of breath (possible thrombosis).
• Unexplained bruising, prolonged bleeding, or blood in stool or urine.
• New or worsening visual disturbances or dizziness.
• Signs of infection, as thrombocytosis may affect immune function.

Tips for Medical Coders

• Code D75.2 is specific to essential thrombocytosis and should not be used for secondary causes of thrombocytosis (e.g., reactive processes or other myeloproliferative disorders).
• Documentation should confirm the diagnosis via laboratory findings (elevated platelets) and exclude secondary causes (e.g., iron deficiency, infection, or inflammation).
• Ensure genetic testing results (e.g., JAK2, CALR, MPL) are documented if available, as they support the diagnosis.
• Avoid coding D75.2 for transient or reactive thrombocytosis; use the appropriate secondary code instead.